Gain a whole new perspective on canine osteoarthritis

Presented by B. Duncan X. Lascelles, BSc, BVSc, PhD, CertVA, DSAS(ST), Dipl. ECVS/ACVS

Continuing education questionnaire

CE credit: 1

AssignedWebcast

Name

First name *

Last name *

License number *

Province where you practise *

Email *

Questions

1. Unlike humans, most cases of canine osteoarthritis result from developmental joint abnormalities making it a young dog's disease. *

True

False

2. If left untreated, chronic OA pain can lead to central nervous system sensitization, thereby increasing resistance to treatment. *

True

False

3. Canine OA is a young dog's disease and the majority of cases are diagnosed between: *

0.5 and 2 years old

2 and 5 years old

5 and 8 years old

8 and 13 years old

4. What are the benefits of implementing the COAST (Canine Osteoarthritis Staging Tool) in my practice? *

Opening the carrier door and dumping the cat out onto the floor

Opening the carrier door, reaching in and scruffing the cat, pulling it out by traction

Improved, standardized approach to diagnosis and monitoring over time

Encompasses early detection and discussion of ‘at risk’ patients

Designed for first opinion practitioners

Team approach

All of the above

5. Timing of analgesic use is not critical. Studies have shown that early pain relief does not prevent deterioration of the musculoskeletal system. *

True

False

6. Use of effective analgesics for a prolonged period of time is contraindicated in the management of Canine OA due to an increased risk of serious adverse drug events. *

True

False

7. Grapiprant, the active ingredient in Galliprant, controls pain and inflammation by blocking: *

Cyclooxygenase enzymes, specifically COX-2

Phospholipase-I enzymes

Prostanoid receptors, specifically EP4 receptors

Antithrombin-III

8. A multimodal approach to manage Canine OA in a young dog lame from elbow dysplasia could include: *

9. In the Target Animal Safety study, up to 15X the daily dose of grapiprant was given to 9 month-old puppies for 9 months, which resulted in no GI ulceration or perforation, no renal failure and no hepatotoxicity. *

True

False

10. In the clinical trial, the majority of GI signs in the Galliprant-treated dogs were classified as mild and resolved after a few days without treatment and none of the adverse events prompted removal of a dog from the study. *

True

False